NCT02074020View on ClinicalTrials.gov

CHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2015

Primary Completion Date

June 30, 2018

Conditions
Systemic Lupus Erythematosus
Interventions
DRUG

Blisibimod

Administered via subcutaneous injection once per week

DRUG

Placebo

Administered via subcutaneous injection once per week

Sponsors
All Listed Sponsors
lead

Anthera Pharmaceuticals

INDUSTRY

NCT02074020 - CHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis | Biotech Hunter | Biotech Hunter